Cancer nanomedicine: from targeted delivery to combination therapy

Sanna, 2014, Targeted therapy using nanotechnology: focus on cancer, Int. J. Nanomed., 9, 467 Farokhzad, 2009, Impact of nanotechnology on drug delivery, ACS Nano, 3, 16, 10.1021/nn900002m Chrastina, 2011, Overcoming in vivo barriers to targeted nanodelivery, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 3, 421, 10.1002/wnan.143 Davis, 2008, Nanoparticle therapeutics: an emerging treatment modality for cancer, Nat. Rev. Drug Discov., 7, 771, 10.1038/nrd2614 Zhang, 2012, Interactions of nanomaterials and biological systems: implications to personalized nanomedicine, Adv. Drug Deliv. Rev., 64, 1363, 10.1016/j.addr.2012.08.005 Chow, 2013, Cancer nanomedicine: from drug delivery to imaging, Sci. Transl. Med., 5, 216rv4, 10.1126/scitranslmed.3005872 Whitehead, 2009, Knocking down barriers: advances in siRNA delivery, Nat. Rev. Drug Discov., 8, 129, 10.1038/nrd2742 Shi, 2011, Differentially charged hollow core/shell lipid–polymer–lipid hybrid nanoparticles for small interfering RNA delivery, Angew. Chem. Int. Ed. Engl., 50, 7027, 10.1002/anie.201101554 Reynolds, 2006, Induction of the interferon response by siRNA is cell type- and duplex length-dependent, RNA, 12, 988, 10.1261/rna.2340906 Kamaly, 2012, Targeted polymeric therapeutic nanoparticles: design, development and clinical translation, Chem. Soc. Rev., 41, 2971, 10.1039/c2cs15344k Rao, 2011, Polymer nanoparticles: preparation techniques and size-control parameters, Prog. Polym. Sci., 36, 887, 10.1016/j.progpolymsci.2011.01.001 Capretto, 2013, Microfluidic and lab-on-a-chip preparation routes for organic nanoparticles and vesicular systems for nanomedicine applications, Adv. Drug Deliv. Rev., 65, 1496, 10.1016/j.addr.2013.08.002 Whitesides, 2006, The origins and the future of microfluidics, Nature, 442, 368, 10.1038/nature05058 Valencia, 2012, Microfluidic technologies for accelerating the clinical translation of nanoparticles, Nat. Nanotechnol., 7, 623, 10.1038/nnano.2012.168 Lim, 2014, Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer, ACS Nano, 8, 6056, 10.1021/nn501371n Valencia, 2013, Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy, ACS Nano, 7, 10671, 10.1021/nn403370e Lim, 2014, Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study, Nanomedicine, 10, 401, 10.1016/j.nano.2013.08.003 Windbergs, 2013, Biodegradable core–shell carriers for simultaneous encapsulation of synergistic actives, J. Am. Chem. Soc., 135, 7933, 10.1021/ja401422r Choi, 2013, One step formation of controllable complex emulsions: from functional particles to simultaneous encapsulation of hydrophilic and hydrophobic agents into desired position, Adv. Mater., 25, 2535, 10.1002/adma.201370119 Harris, 2003, Effect of pegylation on pharmaceuticals, Nat. Rev. Drug Discov., 2, 214, 10.1038/nrd1033 Jokerst, 2011, Nanoparticle PEGylation for imaging and therapy, Nanomedicine, 6, 715, 10.2217/nnm.11.19 Gref, 2000, ‘Stealth’ corona–core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption, Colloids Surf. B. Biointerfaces, 18, 301, 10.1016/S0927-7765(99)00156-3 Peracchia, 1999, Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles, Biomaterials, 20, 1269, 10.1016/S0142-9612(99)00021-6 Bazile, 1995, Stealth Me.PEG–PLA nanoparticles avoid uptake by the mononuclear phagocytes system, J. Pharm. Sci., 84, 493, 10.1002/jps.2600840420 Peracchia, 1999, Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting, J. Control. Release, 60, 121, 10.1016/S0168-3659(99)00063-2 Radovic-Moreno, 2012, Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics, ACS Nano, 6, 4279, 10.1021/nn3008383 Hatakeyama, 2011, A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma, Adv. Drug Deliv. Rev., 63, 152, 10.1016/j.addr.2010.09.001 Yang, 2014, Poly(carboxybetaine) nanomaterials enable long circulation and prevent polymer-specific antibody production, Nano Today, 9, 10, 10.1016/j.nantod.2014.02.004 Keefe, 2012, Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity, Nat. Chem., 4, 59, 10.1038/nchem.1213 Zhu, 2014, A robust graft-to strategy to form multifunctional and stealth zwitterionic polymer-coated mesoporous silica nanoparticles, Biomacromolecules, 15, 1845, 10.1021/bm500209a Yuan, 2012, Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor, Adv. Mater., 24, 5476, 10.1002/adma.201202296 Alexis, 2010, Nanoparticle technologies for cancer therapy, Handb. Exp. Pharmacol., 197, 55, 10.1007/978-3-642-00477-3_2 Rodriguez, 2013, Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles, Science, 339, 971, 10.1126/science.1229568 Hu, 2011, Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform, Proc. Natl. Acad. Sci. U.S.A., 108, 10980, 10.1073/pnas.1106634108 Weiss, 2013, First-in-human Phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer–camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies, Invest. New Drugs, 31, 986, 10.1007/s10637-012-9921-8 Karve, 2012, Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery, Proc. Natl. Acad. Sci. U.S.A., 109, 8230, 10.1073/pnas.1120508109 Acharya, 2011, PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect, Adv. Drug Deliv. Rev., 63, 170, 10.1016/j.addr.2010.10.008 Maeda, 2009, Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect, Eur. J. Pharm. Biopharm., 71, 409, 10.1016/j.ejpb.2008.11.010 Torchilin, 2011, Tumor delivery of macromolecular drugs based on the EPR effect, Adv. Drug Deliv. Rev., 63, 131, 10.1016/j.addr.2010.03.011 Bertrand, 2014, Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology, Adv. Drug Deliv. Rev., 66, 2, 10.1016/j.addr.2013.11.009 Fang, 2011, The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect, Adv. Drug Deliv. Rev., 63, 136, 10.1016/j.addr.2010.04.009 Maeda, 2013, The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo, Adv. Drug Deliv. Rev., 65, 71, 10.1016/j.addr.2012.10.002 Venditto, 2013, Cancer nanomedicines: so many papers and so few drugs!, Adv. Drug Deliv. Rev., 65, 80, 10.1016/j.addr.2012.09.038 Barenholz, 2012, Doxil® – the first FDA-approved nano-drug: lessons learned, J. Control. Release, 160, 117, 10.1016/j.jconrel.2012.03.020 Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS, Cancer Res., 46, 6387 Semple, 2010, Rational design of cationic lipids for siRNA delivery, Nat. Biotechnol., 28, 172, 10.1038/nbt.1602 Coelho, 2013, Safety and efficacy of RNAi therapy for transthyretin amyloidosis, N. Engl. J. Med., 369, 819, 10.1056/NEJMoa1208760 Shi, 2010, Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer, Int. J. Cancer, 126, 2036 Wan, 2013, Lipid nanoparticle delivery systems for siRNA-based therapeutics, Drug Deliv. Transl. Res., 4, 74, 10.1007/s13346-013-0161-z Danquah, 2011, Extravasation of polymeric nanomedicines across tumor vasculature, Adv. Drug Deliv. Rev., 63, 623, 10.1016/j.addr.2010.11.005 Albanese, 2012, The effect of nanoparticle size, shape, and surface chemistry on biological systems, Annu. Rev. Biomed. Eng., 14, 1, 10.1146/annurev-bioeng-071811-150124 Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol., 2, 751, 10.1038/nnano.2007.387 Ge, 2013, Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance, Chem. Soc. Rev., 42, 7289, 10.1039/c3cs60048c Valencia, 2011, Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles, Biomaterials, 32, 6226, 10.1016/j.biomaterials.2011.04.078 Davis, 2009, The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic, Mol. Pharm., 6, 659, 10.1021/mp900015y Davis, 2010, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, Nature, 464, 1067, 10.1038/nature08956 Zhang, 2011, Multimodal nanodiamond drug delivery carriers for selective targeting, imaging, and enhanced chemotherapeutic efficacy, Adv. Mater., 23, 4770, 10.1002/adma.201102263 Leamon, 1991, Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis, Proc. Natl. Acad. Sci. U.S.A., 88, 5572, 10.1073/pnas.88.13.5572 Sega, 2008, Tumor detection using folate receptor-targeted imaging agents, Cancer Metastasis Rev., 27, 655, 10.1007/s10555-008-9155-6 Hrkach, 2012, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile, Sci. Transl. Med., 4, 128ra139, 10.1126/scitranslmed.3003651 Johnston, 2012, Targeting cancer cells: controlling the binding and internalization of antibody-functionalized capsules, ACS Nano, 6, 6667, 10.1021/nn3010476 Steichen, 2012, A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics, Eur. J. Pharm. Sci., 48, 416, 10.1016/j.ejps.2012.12.006 Mahon, 2012, Designing the nanoparticle-biomolecule interface for “targeting and therapeutic delivery”, J. Control. Release, 161, 164, 10.1016/j.jconrel.2012.04.009 Iyer, 2013, Role of integrated cancer nanomedicine in overcoming drug resistance, Adv. Drug Deliv. Rev., 65, 1784, 10.1016/j.addr.2013.07.012 Douillard, 2006, Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer [Adjuvant Navelbine International Trialist Association (ANITA)]: a randomised controlled trial, Lancet Oncol., 7, 719, 10.1016/S1470-2045(06)70804-X Robert, 2006, Randomized Phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer, J. Clin. Oncol., 24, 2786, 10.1200/JCO.2005.04.1764 Valencia, 2013, Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles, Nanomedicine, 8, 687, 10.2217/nnm.12.134 Ma, 2013, Nanoparticles for combination drug therapy, ACS Nano, 7, 9518, 10.1021/nn405674m Feldman, 2011, First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia, J. Clin. Oncol., 29, 979, 10.1200/JCO.2010.30.5961 Batist, 2009, Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors, Clin. Cancer Res., 15, 692, 10.1158/1078-0432.CCR-08-0515 Katragadda, 2013, Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis, PLoS ONE, 8, e58619, 10.1371/journal.pone.0058619 Nishimura, 2013, Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment, Cancer Discov., 3, 1302, 10.1158/2159-8290.CD-13-0159 Landen, 2005, EphA2 as a target for ovarian cancer therapy, Expert Opin. Ther. Targets, 9, 1179, 10.1517/14728222.9.6.1179 Tabernero, 2013, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, Cancer Discov., 3, 406, 10.1158/2159-8290.CD-12-0429 Xu, 2013, Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug, Proc. Natl. Acad. Sci. U.S.A., 110, 18638, 10.1073/pnas.1303958110 Xie, 2010, Error-prone translesion synthesis mediates acquired chemoresistance, Proc. Natl. Acad. Sci. U.S.A., 107, 20792, 10.1073/pnas.1011412107 Doles, 2010, Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy, Proc. Natl. Acad. Sci. U.S.A., 107, 20786, 10.1073/pnas.1011409107 Krishnamachari, 2011, Nanoparticle delivery systems in cancer vaccines, Pharm. Res., 28, 215, 10.1007/s11095-010-0241-4 Harris, 2004, Strategies for resolving patent disputes over nanoparticle drug delivery systems, Nanotechnol. Law Bus., 1, 1